CN113813367B - Composition for treating sensitive skin and preparation method and application thereof - Google Patents

Abstract

The present invention discloses a composition and a preparation method and application thereof. The raw materials for preparing the composition include: 5-20 parts of β-glucan, 5-30 parts of mannan, 8-15 parts of yeast polypeptides and 1-20 parts of sodium hyaluronate. The composition prepared by the present invention repairs damaged skin and treats oral diseases through the above-mentioned raw materials with a specific synergistic effect; it has obvious therapeutic effects in treating sensitive skin, sunburned skin, acne, acne-prone skin, diabetic foot and vascular neuropathic ulcers, superficial wounds and oral ulcers, dental plaque and periodontitis.

Description

A composition for treating sensitive skin and its preparation method and application

Technical Field

The present invention relates to the medical field, and in particular to a composition for treating sensitive skin, and a preparation method and application thereof.

Background technique

In modern society, due to the fast pace of life, high pressure in life and work, irregular work and rest schedules, a large number of skin problems such as skin allergies, sensitive skin, acne, eczema, dermatitis, etc. have emerged. In addition, people's living standards are also improving, and higher demands are put forward for a series of problems caused by skin damage. Among the current solutions, most of the drugs are hormones, which have certain side effects and drug resistance; there are also skin care products such as cosmetics, but they are mainly moisturizing, and the healing effect on damaged skin is poor or the healing time is long. Oral diseases include damage to the oral mucosa such as oral ulcers, tooth decay, oral erosion, bleeding gums, periodontitis, gingivitis, etc. Oral diseases can seriously affect people's quality of life and even bring other complications, such as kidney, coronary artery or liver diseases. The growing oral market is in urgent need of some oral products with outstanding effects and no side effects.

Currently, there is a lack of drugs on the market that can treat both skin diseases and oral diseases. For this reason, the present application proposes a composition with outstanding effects and no side effects, which can effectively promote skin wound healing and also has a certain therapeutic effect on oral diseases.

Summary of the invention

The present invention aims to solve at least one of the technical problems existing in the prior art. To this end, the present invention provides a composition that can effectively promote skin wound healing and also has a certain therapeutic effect on oral diseases.

The invention also provides a method for preparing the composition.

The present invention also provides the application of the composition.

According to the composition of the first aspect of the present invention, the raw materials for preparing the composition include: 5-20 parts of β-glucan, 5-30 parts of mannan, 8-15 parts of yeast polypeptides and 1-20 parts of sodium hyaluronate.

According to some embodiments of the present invention, the composition comprises the following raw materials in mass fractions: 5-10 parts of β-glucan, 15-20 parts of mannan, 8-12 parts of yeast polypeptides and 3-8 parts of sodium hyaluronate.

According to some embodiments of the present invention, the composition comprises the following raw materials in mass fractions: 8-12 parts of β-glucan, 18-22 parts of mannan, 8-12 parts of yeast polypeptides, and 3-6 parts of sodium hyaluronate.

According to some embodiments of the present invention, the composition comprises the following raw materials in mass fractions: 10 parts of β-glucan, 20 parts of mannan, 10 parts of yeast polypeptides, and 5 parts of sodium hyaluronate.

According to some embodiments of the present invention, the raw materials for preparing the composition further include: glycerin, carbomer, sodium methylparaben and/or triethanolamine.

According to some embodiments of the present invention, the composition further comprises the following raw materials in mass fractions: 5-15 parts of carbomer, 20-40 parts of glycerol, 1-5 parts of sodium methylparaben and 5-20 parts of triethanolamine.

According to some embodiments of the present invention, the composition further comprises the following raw materials in mass fractions: 30 parts of glycerol, 10 parts of carbomer, 1 part of sodium methylparaben and 15 parts of triethanolamine. Triethanolamine and carbomer form a stable emulsified structure to block the skin from external bacteria to form a physical isolation, sodium methylparaben is an antibacterial agent and preservative, and glycerol is a moisturizer.

According to some embodiments of the present invention, the carbomer is selected from one of the following ingredients: carbomer 940, carbomer 941, carbomer 934, preferably, the carbomer is carbomer 941.

According to some embodiments of the present invention, the dosage form of the composition is one of ointment, foam, aerosol, powder, solution, emulsion and slurry.

According to some embodiments of the present invention, the β-glucan is derived from a yeast cell wall extract and has a molecular weight of less than 500,000 Da. Preferably, the β-glucan has a molecular weight of less than 200,000 Da.

According to some embodiments of the present invention, the mannan is derived from a yeast cell wall extract and has a molecular weight of less than 500,000 Da. Preferably, the β-glucan has a molecular weight of less than 200,000 Da.

According to the second aspect of the present invention, the preparation method of the above-mentioned composition comprises the following steps: mixing β-glucan, mannan, yeast polypeptides, sodium hyaluronate, carbomer, glycerin, sodium hydroxybenzoate and triethanolamine.

According to the application of the third aspect of the present invention, the application is the application of the above composition for preparing a drug for promoting skin wound healing.

According to some embodiments of the present invention, the application is the application of the above composition for preparing a medicine for treating burns.

According to some embodiments of the present invention, the application is application of the above composition in the preparation of a drug for skin repair.

According to some embodiments of the present invention, the application is application of the above composition in the preparation of skin care drugs.

According to some embodiments of the present invention, the application is application in preparing a medicine for treating oral diseases.

According to some embodiments of the invention, the oral disease is oral ulcer, periodontitis and dental caries.

A medicine for promoting skin wound healing, comprising the above composition.

According to some embodiments of the present invention, the drug for promoting skin wound healing also includes one or more of pharmaceutically and/or dermatologically acceptable moisturizers, emollients, surfactants, rheology modifiers, skin penetration enhancers, flavoring agents, water-soluble film-forming polymers, preservatives, pH regulators, or fragrances.

The beneficial effects of the present invention are as follows: the composition prepared by the present invention repairs damaged skin and treats oral diseases through a specific synergistic effect through β-glucan, mannan, yeast polypeptides, sodium hyaluronate, carbomer, glycerol, sodium hydroxybenzoate and triethanolamine. The composition includes using yeast β-glucan to induce the expression of TNF-α in wound macrophages, mannan has the functions of anti-virus, promoting wound healing and anti-oxidation, and β-glucan and mannan produce obvious synergistic effects, which can play a significant role in skin care and repair, and can also effectively inhibit the formation of dental plaque, inhibit the growth of Streptococcus mutans, oral Candida and Porphyromonas, and have a significant therapeutic effect on oral diseases such as the formation of caries, periodontitis, and oral ulcers. The β-glucan and mannan used in the scheme of the present invention are both of edible grade, derived from yeast, and are naturally safe. The composition prepared by the scheme of the present invention has obvious therapeutic effects in treating chronic ulcer wounds and superficial wounds such as sensitive skin, sunburned skin, acne, acne-prone skin, diabetic foot and vascular neuropathic ulcers, as well as in treating oral ulcers, periodontitis, gingivitis and preventing dental caries.

Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein:

FIG1 is a graph showing the effect of the composition prepared in Example 1 of the test example of the present invention on a cell scratch test;

FIG2 is a graph showing the effect of the composition prepared in Comparative Example 1 in the test examples of the present invention on the cell scratch test;

FIG3 is a graph showing the effect of the composition prepared in Comparative Example 2 on the cell scratch test in the test examples of the present invention;

FIG4 is a graph showing the effect of the composition prepared in Comparative Example 3 on the cell scratch test in the test examples of the present invention;

FIG5 is a diagram showing the treatment results of superficial scratches by the composition prepared in Example 1 of the test example of the present invention;

FIG6 is a graph showing the treatment results of burns by the composition prepared in Example 1 of the test example of the present invention;

FIG. 7 is a diagram showing the effect of the composition prepared in Example 1 of the test example of the present invention on the coloring of dental plaque on teeth before and after brushing.

Detailed ways

The following will clearly and completely describe the concept of the present invention and the technical effects produced in combination with the embodiments, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by technicians in this field without creative work are all within the scope of protection of the present invention. The test methods used in the embodiments are all conventional methods unless otherwise specified; the materials, reagents, etc. used, unless otherwise specified, can all be reagents and materials obtained from commercial channels.

Example 1

An embodiment of the composition of the present invention contains the following components in weight percentage: 1% β-glucan, 2% mannan, 1% yeast polypeptides, 0.5% sodium hyaluronate, 1% carbomer 941, 3% glycerol, 0.1% sodium methylparaben and 1.5% triethanolamine, and the balance is water.

The preparation method of the composition in this embodiment is as follows:

(1) Add an appropriate amount of purified water to a mixing tank, then add 1% Carbomer 941, stir at 80°C to dissolve, and keep at 80°C for 30 minutes, then turn on the cooling water to cool down;

(2) Add 1% β-glucan, 2% mannan, 1% yeast polypeptide, 0.5% sodium hyaluronate, 3% glycerol, 0.1% sodium methylparaben, 1.5% triethanolamine, and the balance of water into a stirring tank to dissolve the components;

(3) The mixture obtained in steps (1) and (2) was mixed and stirred for 10 minutes.

Example 2

An embodiment of the composition prepared by the present invention contains the following components in weight percentage: 1% β-glucan, 1% mannan, 1% yeast polypeptides, 0.5% sodium hyaluronate, 1% carbomer 941, 3% glycerol, 0.1% sodium methylparaben and 1.5% triethanolamine, and the balance is water.

The preparation method of the composition in this example is the same as that in Example 1.

Example 3

An embodiment of the composition prepared by the present invention contains the following components in weight percentage: 2% β-glucan, 1% mannan, 1% yeast polypeptides, 0.5% sodium hyaluronate, 1% carbomer 941, 3% glycerol, 0.1% sodium methylparaben and 1.5% triethanolamine, and the balance is water.

The preparation method of the composition in this example is the same as that in Example 1.

Example 4

An embodiment of the composition of the present invention comprises the following components in weight percentage: 1% β-glucan, 1% mannan, 1% yeast polypeptides, 0.2% sodium hyaluronate, 1% carbomer 941, 2% glycerol, 0.1% sodium methylparaben and 1.5% triethanolamine, and the balance is water.

The preparation method of the composition in this example is the same as that in Example 1.

Example 5

An embodiment of the composition of the present invention comprises the following components in weight percentage: 1% β-glucan, 1% mannan, 0.5% yeast polypeptides, 2% sodium hyaluronate, 1% carbomer 941, 1% glycerol, 0.1% sodium methylparaben and 1.5% triethanolamine, and the balance is water.

The preparation method of the composition in this example is the same as that in Example 1.

Comparative Example 1

A comparative example of the composition of the present invention, the difference between this comparative example and Example 1 is that β-glucan is removed from the raw materials for preparation. The sources of the remaining components and the preparation method of the composition are the same as those of Example 1.

Comparative Example 2

A comparative example of the composition of the present invention, the difference between this comparative example and Example 1 is that mannan is removed from the preparation raw materials. The sources of the remaining components and the preparation method of the composition are the same as those of Example 1.

Comparative Example 3

A comparative example of the composition of the present invention, the difference between this comparative example and Example 1 is that β-glucan and mannan are removed from the preparation raw materials. The sources of the remaining components and the preparation method of the composition are the same as those of Example 1.

Test Case

1. Test on promoting skin repair activity

(1) Promote the proliferation of human skin fibroblasts (HSF) (MTT test)

Take the cells in the logarithmic growth phase, digest them, and use DMEM medium containing 10% fetal bovine serum and 1% double antibody to make a cell suspension with a concentration of 1×10 ⁵ /mL, inoculate them in a 96-well plate, 150μL per well, and culture them in a 37°C, 5% CO ₂ incubator for 24h. Replace the culture medium with 100μg/mL experimental group, negative control group (containing an equal amount of cell suspension) and blank control group (containing an equal amount of 1% double antibody DMEM culture medium). The experimental group was added with Example 1, Example 2, Example 3, Comparative Example 1, Comparative Example 2 and Comparative Example 3, respectively, and the negative control group and blank control group were added with 1% double antibody DMEM culture medium to each well for continued culture. Each group has at least 3 duplicate wells, and after oscillation, continue to culture for 24h and 48h, aspirate the culture medium, wash with PBS, add 20μL MTT solution (5mg/mL)/well, culture at 37°C, 5% CO ₂ for 4h, aspirate the supernatant, add 150μL DMSO to each well, and shake on a shaker for 10min to fully dissolve the crystals. The absorbance of each well was measured at 490 nm using an ELISA reader. A blank group experiment without sample solution was performed at the same time, and the proliferation survival rate was calculated according to the calculation formula shown below. The experiment was repeated 3 times.

Proliferation survival rate (%) = (absorbance value of experimental group - absorbance value of blank group) / (absorbance value of negative control group - absorbance value of blank group) × 100%.

Table 1

Note: Compared with the negative control group, ^* P＜0.05, ^** P＜0.01, ^▲ P＞0.05

The results of the experimental group on the proliferation and survival rate of HSF at different action times are shown in Table 1. It can be seen from the table that compared with the negative control group, the 24 and 48h experimental groups have a proliferation promoting effect on HSF (p < 0.05), and the effect is better after 48h of administration. 24h Comparative Example 3 has no proliferation promoting effect (p > 0.05), and the 24h and 48h Example 1 has a proliferation promoting effect on HSF that is significantly greater than that of Comparative Example 1, Comparative Example 2 and Comparative Example 3. The proliferation promoting effect of Example 1 is the best, followed by Example 3. The three examples are compared with Comparative Example 1 (lacking yeast β-glucan), Comparative Example 2 (lacking yeast mannan) and Comparative Example 3 (lacking yeast β-glucan and yeast mannan). The proliferation promoting effect of the three examples has a more obvious advantage. At the same time, when the weight ratio of yeast β-glucan to yeast mannan is 1:2, it can produce a good proliferation promoting effect on human skin fibroblasts.

(2) Promote the migration of human skin fibroblasts (cell scratch test)

Cells in logarithmic growth phase were obtained and digested. A cell suspension with a concentration of 1×10 ⁵ /mL was prepared with a DMEM medium containing 15% fetal bovine serum and 1% double antibody, and the suspension was inoculated in a 6-well plate with 2 mL per well. After culturing in a 37°C, 5% CO ₂ incubator for 24 h, a 1 mL pipette tip was used to gently scratch the center of each culture well, washed with PBS, and 2 mL of a DMEM medium containing 100 μg/mL of the composition (the composition prepared in Example 1, control group 1, control group 2 and control group 3), 15% fetal bovine serum and 1% double antibody was added. The blank group was added with 2 mL of a DMEM medium containing 15% fetal bovine serum and 1% double antibody. Three replicate wells were added for each well. After continuing to culture for 24 h, the wells were observed and photographed under an inverted microscope.

The results of the cell scratch test are shown in Figures 1-4. It can be seen from the figures that the cells added with the composition prepared in Example 1 have the fastest migration speed, indicating that the healing effect on wounded skin is the most significant.

2. Free radical scavenging effect test

1. Experimental materials: The compositions prepared in Example 1 and Comparative Examples 1 to 3 were dissolved in water to prepare 5% aqueous solutions as samples to be tested.

2. Experimental process:

(1) Hydroxyl free radical scavenging experiment: Take 0.5 ml of 0.75 mmol/L anhydrous ethanol solution of o-phenanthroline in a stoppered test tube, add 2 ml of 0.2 mol/L phosphate buffer (pH = 7.4) and 1 ml of the sample to be tested, mix thoroughly, then add 0.5 ml of 0.75 mmol/L FeSO ₄ ·7H ₂ O solution, mix again, add 0.5 ml of 0.01% (v/v) H ₂ O ₂ , react in a constant temperature water bath at 37°C for 60 min, and measure the absorbance of each group of mixture solutions at 536 nm, recorded as Ax. Distilled water was used as the blank group to measure the absorbance, recorded as Ab. Distilled water was used as the _damaged group to measure the absorbance, recorded as An. The _hydroxyl free radical scavenging rate was calculated according to the formula: hydroxyl free radical scavenging rate = (Ax-An)/(Ab-An)×100%.

(2) DPPH free radical scavenging experiment: Take 3 ml of 0.2 mmol/L DPPH anhydrous ethanol solution in a cuvette, then add 1 ml of the sample to be tested, mix well, and react at room temperature in the dark for 30 min. Measure the absorbance at a wavelength of 517 nm and record it as Ax; use 3 ml of anhydrous ethanol and 1 ml of the sample to be tested as a blank control and measure the absorbance, which is recorded as Ab; use 3 ml of DPPH anhydrous ethanol solution and 1 ml of anhydrous ethanol solution as a control group and measure the absorbance, which is recorded as An. Calculate the DPPH free radical scavenging rate according to the formula: DPPH free radical scavenging rate = [1-(Ax-Ab)/An] × 100%.

Table 2 Determination of free radical scavenging effect of the composition

Note: P is less than 0.05.

3. Experimental results: The results of DPPH free radical scavenging are shown in Table 2. It can be seen from the table that the scavenging rates of the composition prepared in Example 1 of the present invention for hydroxyl free radicals and DPPH free radicals are both above 80%, which can significantly delay the aging of skin cells; while the scavenging rates of hydroxyl free radicals and DPPH free radicals of the comparative examples 1 to 3, which respectively change the components of the composition, are significantly reduced, indicating that the technical effect of the present application scheme is achieved through the synergistic effect of β-glucan and mannan.

3. In vitro percutaneous absorption test

A vertical modified Franz diffusion cell (20 mL) and ex vivo skin from the abdomen of a suckling pig were used. The ex vivo skin was fixed between the sample cell and the receiving cell, with the stratum corneum facing the sample cell. The test gel was evenly applied, and the back of the skin was in close contact with the receiving solution (0.9% sodium chloride injection) (no bubbles were allowed). The effective diffusion area was about 3 cm ² , and the receiving system was placed in a constant temperature system at 32°C ± 0.5°C, with electromagnetic stirring at a speed of 400 rpm. 1 mL of the receiving solution was taken after 1 hour, and the test was terminated at the same time. The suckling pig skin was immediately taken out, and the residual gel on the epidermis was cleaned, and the receiving solution was fixed to 10 mL. After high-speed centrifugation (10,000 rpm) for 5 minutes, the supernatant was taken and filtered to obtain the intradermal residual determination solution.

The HPLC differential detection method was used to calculate the content of β-glucan and mannan in the receiving solution by peak area according to the external standard method, and the skin permeation rate was calculated. Skin permeation rate = content in the receiving solution/sample content × 100%.

table 3

The experimental results are shown in Table 3, from which it can be seen that the formula of the composition of the scheme of the present invention has an obvious coordination and synergistic effect.

4. Antibacterial test

It is used to test the antibacterial activity of Example 1 and Comparative Examples 1-3 against oral pathogens, taking Porphyromonas endodonticus and Streptococcus mutans as examples.

Porphyromonas endodonticus was suspended in brain heart infusion broth and cultured at 37°C for 48h; Streptococcus mutans was suspended in trypticase soy broth and cultured at 37°C for 48h; centrifuged at 3000r/min for 10min, the supernatant was discarded, and the bacterial solution was reserved. The experiment was divided into 10 groups, namely Example 1, Comparative Examples 1-3 and control group normal saline. The samples of Example 1 and Comparative Examples 1-3 were all prepared into aqueous solutions with equal bacterial concentrations. 6mm diameter circular filter paper pieces sterilized at 121°C for 15min were soaked in 1ml of aqueous solution and normal saline of each embodiment and comparative example, 5 filter paper pieces for each solution, and taken out and drained after 5min. Use sterile cotton swabs to dip the prepared Porphyromonas endodonticus and Streptococcus mutans bacterial solutions, lightly draw parallel cross lines in 4 directions on the blood agar plate, and evenly spread them. The filter paper pieces soaked with different sample solutions were placed on the surface of the inoculated bacterial agar plate. The experiment was repeated 6 times for each sample for each bacterium. Each plate was placed in a 37°C incubator for 48 h, and the diameter of the inhibition zone on each plate was measured with a vernier caliper.

Table 4

Note: *P is less than 0.05.

The experimental results are shown in Table 4. It can be seen from the table that Example 1 has the most obvious inhibitory effect on Porphyromonas endodonticus and Streptococcus mutans, while Porphyromonas and Prevotella are considered to be periodontal pathogens. The formation of dental plaque by oral microorganisms on the surface of teeth is the cause of dental caries. Under the condition that dental plaque is in severe acidification for a long time, acidophilic microorganisms such as Streptococcus mutans will dominate. If the formation of dental plaque is avoided from the root and the growth of Streptococcus mutans is inhibited, the formation of dental caries will be significantly prevented. The experimental results show that the composition prepared in Example 1 has a good application prospect in the preparation of drugs for treating oral diseases.

5. Clinical trials

(1) Experiment on promoting skin wound healing

60 patients with superficial scratches were selected and randomly divided into an observation group and a control group, 30 cases in each group, and the age of the patients was between 20 and 55 years old. The control group was smeared with commercially available skin repair drugs, and the observation group was smeared with Example 1, which was applied to the damaged skin and the surrounding area twice a day for a total of 10 days.

Observation indicators: Compare the treatment effects and skin function test results of the two groups of patients.

Markedly effective: After treatment, all damaged skin of the patient healed without any scars remaining.

Effective: After treatment, all the damaged skin of the patients healed and the scars were significantly improved.

Ineffective: The patient's damaged skin did not improve after treatment.

Results: The treatment effect of the control group was significantly lower than that of the observation group, and there was no statistical difference between the two groups (p < 0.05). The treatment effect of the patients is shown in Table 5:

table 5

Note: p＜0.05.

As can be seen from Table 5, the repair effect of the observation group on traumatic skin was better than that of the control group, and the data between the two groups were statistically significant (p < 0.05).

A 5-year-old patient with superficial scratches was selected as the informed consent patient and smeared with the composition prepared in Example 1 of the present application scheme. The experimental results are shown in Figure 5. It can be seen from the figure that the wound of the scratched patient returned to normal after 3 days of use.

(2) Effect of application on burns

A scald patient was selected, who gave informed consent, and the composition prepared in Example 1 of the present application was applied three times a day to evenly cover the surface skin. The experimental results are shown in FIG6 . It can be seen from the figure that after 10 days of use, the wound of the scald patient healed and the surface skin basically returned to normal.

(3) Experiment on inhibiting the formation of dental plaque

20 subjects aged 20 to 55 were selected to compare the plaque coloring effect of dental plaque on teeth before and after brushing with the composition prepared in Example 1 using a plaque display liquid (Wuhan Yadian Biotechnology Co., Ltd., trade name Yan Di). The experimental results are shown in Figure 7. It can be seen from the figure that after brushing teeth for 2 to 3 minutes every day with the composition prepared in Example 1, the red dental plaque attached to the teeth was significantly reduced after 1 month, indicating that the composition prepared in the scheme of the present invention can inhibit the formation of dental plaque on the tooth surface and can effectively prevent dental caries, bad breath and oral inflammation.

The yeast β-glucan and yeast mannan used in the examples and comparative examples of the present invention are both conventional products available on the market.

The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.

Claims (5)

1. A composition, characterized in that the composition is composed of the following raw materials in percentage by weight: 1% β-glucan, 2% mannan, 1% yeast polypeptides, 0.5% sodium hyaluronate, 1% carbomer 941, 3% glycerol, 0.1% sodium methylparaben, 1.5% triethanolamine and 89.9% water. 2. A method for preparing the composition according to claim 1, characterized in that it comprises the following steps: S1: Add part of the water to a stirring tank, then add 1% Carbomer 941, stir at 80°C to dissolve, and keep at 80°C for 30 minutes, turn on the cooling water to cool down, and obtain mixture 1; S2: 1% β-glucan, 2% mannan, 1% yeast polypeptide, 0.5% sodium hyaluronate, 3% glycerol, 0.1% sodium methylparaben, 1.5% triethanolamine and the balance of water are added into a stirring tank to dissolve the components to obtain a mixture 2; S3: Mixture 1 obtained in step S1 and mixture 2 obtained in step S2 are mixed and stirred for 10 minutes to obtain a composition. 3. Use of the composition according to claim 1 in preparing a drug for promoting skin wound healing. 4. Use of the composition according to claim 1 in preparing a medicine for treating scalds. 5. Use of the composition according to claim 1 in preparing a medicament for treating oral diseases, characterized in that the oral diseases are oral ulcers, periodontitis and dental caries.